Peter Ellinghaus

Darmstadt, HE, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Targeted therapy for biliary tract cancer: facts and fictions as well as demands and challenges.

Targeted therapy for biliary tract cancer: facts and fictions as well as demands and challenges.

Journal: Expert review of anticancer therapy

Published: November 25, 2025

Rogaratinib Plus Atezolizumab in Cisplatin-Ineligible Patients With FGFR RNA-Overexpressing Urothelial Cancer: The FORT-2 Phase 1b Nonrandomized Clinical Trial.

Rogaratinib Plus Atezolizumab in Cisplatin-Ineligible Patients With FGFR RNA-Overexpressing Urothelial Cancer: The FORT-2 Phase 1b Nonrandomized Clinical Trial.

Journal: JAMA oncology

Published: February 20, 2024

FGFR inhibitor resistance in cholangiocarcinoma: current understanding and future directions.

FGFR inhibitor resistance in cholangiocarcinoma: current understanding and future directions.

Journal: Expert opinion on pharmacotherapy

Published: September 15, 2023

FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1/3 mRNA Expression.

FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1/3 mRNA Expression.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: October 14, 2022

Patient Selection Approaches in FGFR Inhibitor Trials-Many Paths to the Same End?

Patient Selection Approaches in FGFR Inhibitor Trials-Many Paths to the Same End?

Journal: Cells

Published: September 14, 2022

Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study.

Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study.

Journal: The Lancet. Oncology

Published: April 12, 2019

Rogaratinib: A potent and selective pan-FGFR inhibitor with broad antitumor activity in FGFR-overexpressing preclinical cancer models.

Rogaratinib: A potent and selective pan-FGFR inhibitor with broad antitumor activity in FGFR-overexpressing preclinical cancer models.

Journal: International journal of cancer

Published: September 07, 2018

New pulmonary hypertension model in conscious dogs to investigate pulmonary-selectivity of acute pharmacological interventions.

New pulmonary hypertension model in conscious dogs to investigate pulmonary-selectivity of acute pharmacological interventions.

Journal: European journal of applied physiology

Published: September 10, 2017

FGF23 expression in rodents is directly induced via erythropoietin after inhibition of hypoxia inducible factor proline hydroxylase.

FGF23 expression in rodents is directly induced via erythropoietin after inhibition of hypoxia inducible factor proline hydroxylase.

Journal: PloS one

Published: May 31, 2017

Potential biomarkers of haemophilic arthropathy: correlations with compatible additive magnetic resonance imaging scores.

Potential biomarkers of haemophilic arthropathy: correlations with compatible additive magnetic resonance imaging scores.

Journal: Haemophilia : the official journal of the World Federation of Hemophilia

Published: February 02, 2016

Expression of pro-inflammatory genes in human endothelial cells: Comparison of rivaroxaban and dabigatran.

Expression of pro-inflammatory genes in human endothelial cells: Comparison of rivaroxaban and dabigatran.

Journal: Thrombosis research

Published: January 25, 2016

Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy.

Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy.

Journal: Oncogenesis

Published: January 21, 2016

Showing 1-12 of 21

Last Updated: 09/26/2026